<DOC>
	<DOCNO>NCT02544789</DOCNO>
	<brief_summary>Outcomes child relapsed/refractory ( R/R ) acute lymphoblastic leukemia ( ALL ) dismal . Therefore , investigator perform multicenter , phase II study evaluate efficacy , safety pharmacokinetic clofarabine Chinese pediatric patient R/R ALL</brief_summary>
	<brief_title>Clofarabine Chinese Pediatric Patients With Refractory Relapsed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Pediatric patient ( young 21 year old ) acute lymphoblastic leukemia confirm histology Refractory relapse acute lymphocytic leukemia receive least two drug treatment No prior chemotherapy within 2 week entry resolution toxic effect prior therapy Normal cardiac function , adequate hepatic function [ total bilirubin ≤1.5× upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3ULN ] renal function ( serum creatinine ≤ 2 ULN ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy 3 month AEs recover prior therapy Within 3 month allogeneic autologous stem cell transplantation With central nervous involvement uncontrolled infection Patients use clofarabine allergic fludarabine cladribine</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>